DDrare: Database of Drug Development for Rare Diseases

56. ベーチェット病
［臨床試験数：68，薬物数：87（DrugBank：31），標的遺伝子数：36，標的パスウェイ数：113］

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2387066; 3400935113276; 8699505952864; AIN457; APREMILAST; Adalimumab; Allogeneic Stem Cell Transplant; Alpha interferon; Anakinra; Apremilast; Apremilast (CC-10004); Autologous Stem Cell Transplant; Autologous Stem Cell Transplantation; BFGF; CANAKINUMAB; CC; CC-10004; Calcium; Canakinumab; Colchicine; Cyclophosphamide; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine Pill; Cytotoxic Combination; Daclizumab; Dextrose; Entecavir; Etanercept; Etanercept, Methotrexate, Prednisolone; Flucinolone acetonide; GEVOKIZUMAB; GSK1070806; Gevokizumab; Golimumab; Golimumab (GOL); Hemay005; Hydroxychloroquine; IL-2; INTERLEUKIN 2; Ilaris; Infliximab; Interferon Alfa-2A; Interferon alfa; Interferon alfa-2a; Interferon alpha-2a; Interferon-alpha2a; Interleukin 2; Intravitreal Infliximab; J1081; Low-dose IL-2; Methotrexate; Methylorednisolone; Otezla; Other: dextrose water 5%; Other: serum levels of angiogenin, bFGF, VEGF; Pentoxifylline; Prednisolone; Radiation: Diode laser 980nm&100 mWatt; Remicade; Remicade 100 mg; RhumAb to Il-17A (IgG1-k-class); Rituximab; Roferon-A; Roferon-A 3miu; Roferon-A, 3miu; Roferon-A, 4.5miu; Roferon-A, 6miu; Rosuvastatin; Rosuvastatin calcium 40mg; S78989; STELARA; Stelara; Subcutaneous Ustekinumab; TA-650; Thalidomide; Tocilizumab; Tocilizumab (TCZ); Topical Pentoxifylline Gel (Vehicle +PTX); Triamcinolone; Triamcinolone Acetonide; Ustekinumab; Veldona; Veldona,; Water; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000031637	2020-04-10	1990-01-01	Behcet’s Uveitis Therapy (BUT) Study	Behcet’s Uveitis Therapy (BUT) Study	Uveitis in Behcet’s Disease	Arm A: Interferon Alpha-2a;Arm B:Adalimumab;Arm C:Cyclosporine;	The First Affiliated Hospital of Chongqing Medical University	NULL	Pending			Both	Arm A:90;Arm B:90;Arm C:90;	Phase 4	China
2	NCT03209219 (ClinicalTrials.gov)	June 30, 2017	4/7/2017	Interferon a2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis	Randomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis	Behçet Disease;Uveitis	Drug: Interferon Alfa -2A;Drug: Cyclosporine Pill	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	65 Years	All	36	Phase 3	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000031637

2020-04-10

1990-01-01

Behcet’s Uveitis Therapy (BUT) Study

Uveitis in Behcet’s Disease

Arm A: Interferon Alpha-2a;Arm B:Adalimumab;Arm C:Cyclosporine;

The First Affiliated Hospital of Chongqing Medical University

NULL

Pending

Both

Arm A:90;Arm B:90;Arm C:90;

Phase 4

China

NCT03209219
(ClinicalTrials.gov)

June 30, 2017

4/7/2017

Interferon a2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

Randomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis

Behçet Disease;Uveitis

Drug: Interferon Alfa -2A;Drug: Cyclosporine Pill

Peking Union Medical College Hospital

NULL

Recruiting

18 Years

65 Years

All

Phase 3

China